NeuroScientific Biopharmaceuticals Limited announced the resignation of its CEO Stephen Carter. Stephen has notified the Board that he will be resigning from the role effective 31 December 2023. During the month of December 2023 Stephen will oversee the preparation of the documents necessary to make the Investigational New Drug (IND) submission to the US Food and Drug Administration (FDA) in first quarter of 2024.